title: Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
abstract: The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. Evidence suggests that immunotherapy is most beneficial alone when employed early in the disease process or in combination with standard therapies (eg, radiation) later in the disease process. Indeed, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. As monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in crosspriming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses. Learning how to exploit radiation-induced changes to tumor-cell antigens, and how to induce effective immune responses to these cumulatively immunogenic stimuli, is an exciting frontier in cancer therapy research. This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well as preclinical systems demonstrating that immunotherapy can be effectively combined with radiation therapy. Finally, we review current clinical trials where standard-of-care radiation therapy is being combined with immunotherapy.
authors.affiliation: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: James W
authors.initials: JW
authors.lastname: Hodge
authors.forename: Chandan
authors.initials: C
authors.lastname: Guha
authors.forename: Jacques
authors.initials: J
authors.lastname: Neefjes
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000532:radiotherapy*; D011839:Radiation, Ionizing; D011878:Radiotherapy / Q000379:methods*; D018714:Radiotherapy, Adjuvant
chemical_list: D000911:Antibodies, Monoclonal
references.citation: Cell Death Differ. 2008 Jan;15(1):3-12
references.pmid: 18007663
references.citation: Nat Med. 1998 May;4(5):581-7
references.pmid: 9585232
references.citation: Cell Immunol. 1995 Oct 15;165(2):243-51
references.pmid: 7553889
references.citation: Nat Med. 2007 Sep;13(9):1050-9
references.pmid: 17704786
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3964-73
references.pmid: 11099326
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5284-91
references.pmid: 18698048
references.citation: J Exp Med. 2005 Oct 3;202(7):907-12
references.pmid: 16203864
references.citation: Nat Med. 2007 Jan;13(1):54-61
references.pmid: 17187072
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1493-502
references.pmid: 17332294
references.citation: J Immunother. 2005 Mar-Apr;28(2):129-35
references.pmid: 15725956
references.citation: J Nucl Med. 1993 Jul;34(7):1031-6
references.pmid: 7686217
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4241-9
references.pmid: 18594006
references.citation: J Natl Cancer Inst. 1995 Feb 15;87(4):280-5
references.pmid: 7707419
references.citation: J Immunol. 1998 Aug 1;161(3):1083-6
references.pmid: 9686565
references.citation: Int Immunol. 2000 Nov;12(11):1539-46
references.pmid: 11058573
references.citation: Trends Immunol. 2005 Feb;26(2):111-7
references.pmid: 15668127
references.citation: J Immunol. 2002 Oct 1;169(7):3760-70
references.pmid: 12244170
references.citation: J Immunother. 2000 Sep-Oct;23(5):570-80
references.pmid: 11001550
references.citation: Radiat Res. 2006 Dec;166(6):819-31
references.pmid: 17149971
references.citation: Clin Cancer Res. 2005 May 1;11(9):3353-62
references.pmid: 15867235
references.citation: Immunity. 2001 Mar;14(3):303-13
references.pmid: 11290339
references.citation: Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S171-8
references.pmid: 15127241
references.citation: Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):655-66
references.pmid: 16199306
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):767-77
references.pmid: 10837963
references.citation: Radiother Oncol. 1999 Feb;50(2):199-204
references.pmid: 10368044
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
references.pmid: 14967443
references.citation: Int J Radiat Biol. 2007 Nov-Dec;83(11-12):819-25
references.pmid: 17852561
references.citation: Pharmacol Ther. 1999 Apr;82(1):97-106
references.pmid: 10341360
references.citation: Cancer Res. 2004 Nov 1;64(21):7985-94
references.pmid: 15520206
references.citation: J Leukoc Biol. 2005 Mar;77(3):361-8
references.pmid: 15569694
references.citation: J Exp Med. 1999 Mar 1;189(5):797-802
references.pmid: 10049943
references.citation: Expert Rev Mol Med. 2000 Apr 19;2(3):1-24
references.pmid: 14585140
references.citation: Cancer Res. 2004 Jun 15;64(12):4328-37
references.pmid: 15205348
references.citation: J Immunol. 2003 Jun 15;170(12):6338-47
references.pmid: 12794167
references.citation: Oncogene. 2008 Jan 7;27(2):200-7
references.pmid: 18176601
references.citation: Int Immunopharmacol. 2003 Aug;3(8):1093-1104
references.pmid: 12860166
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5280-9
references.pmid: 17875756
references.citation: J Exp Med. 2006 May 15;203(5):1259-71
references.pmid: 16636135
references.citation: Eur J Histochem. 1994;38 Suppl 1:53-60
references.pmid: 8547711